Clinical Perspectives

Some Cancer Symptoms More Likely to Present in Emergency Rooms

Emergency room providers are increasingly diagnosing cancer symptoms in patients. It is important that ER providers refer these patients to a cancer...

Understanding Chronic Myelogenous Leukemia (CML)

Chronic myeloid leukemia often doesn’t produce noticeable symptoms in its early stages. In fact, many patients don’t realize there is a problem until...

Refining Multiple Myeloma Treatments: the EMMA Created at Moffitt

A result of Mark Pentecost’s generous donation, the EMMA database tests a multiple myeloma patient’s sensitivity to dozens of drugs at one time to...

Lung Nodules and Lung Cancer Early Detection

The Lung Nodule Clinic in the Lung Cancer Early Detection Center at Moffitt is focused on evaluating patients with newly-discovered lung nodules.

Immune Checkpoint Inhibitor Targeting LAG3 May Lead to Therapeutic Approaches in Advanced Melanoma

Moffitt researchers have become the first in the world to visualize the molecular structure of the LAG3 protein. Their findings reveal several...

Research Presented on Baseline Metastatic Patterns and Clinical Outcomes Among BRAF-Positive Metastatic Melanoma Patients

Dr. Zeynep Eroglu shares her research findings evaluating the association between baseline metastatic patterns and outcomes among BRAF+ metastatic...

11-Gene Expression Signature May Predict Sentinel Lymph Node Metastatic Status in Melanoma Patients

Dr. Ahmad Tarhini, a medical oncologist in the Cutaneous Oncology Department, shares research findings looking at biomarkers derived from primary...

Advancements in Treatment for Breast and Gynecologic Cancers

Gynecologic Oncology Program Chair Dr. Robert Wenham presents treatment advancements using antibody-drug conjugates (ADCs) in HER2-positive breast...

Moffitt Researcher Receives Grant to Study Immunogenic Activity of Oncolytic Virus and Immune Checkpoint Blockade

Dr. Roger Li, a genitourinary oncology surgeon at Moffitt Cancer Center, received a grant from the Department of Defense to study the immunogenic...

Cellular Immunotherapy Highlights from ASCO

Moffitt’s physicians and scientists were proud to share and present their cellular immunotherapy research findings at American Society of Clinical...

Malignant Hematology ASCO Highlights

Moffitt’s Malignant Hematology physicians and scientists were proud to share and present their research findings at American Society of Clinical...

Gastrointestinal Oncology Presented Research Studies at ASCO 2022

Gastrointestinal oncologists, fellow and radiologists presented exciting findings at ASCO 2022.

Bladder Cancer Treatment Advancement Roundup

At the recent ASCO 2022, there was a lot of excitement about the novel immunotherapy treatment advancements in genitourinary oncology. Learn more...

Gut Microbiome/Metabolome Predicts Response to Immune Checkpoint Blockers in Patients with Recurrent Metastatic Head and Neck Squamous Cell Cancer

Research presented at ASCO demonstrates gut microbial signatures associated with ICB response was found in patients with RM HNSCC.

Phase 1 Dose-Escalation/Expansion Study of CUE-101 Given in Patients with Recurrent/Metastatic HPV16+ Head and Neck Cancer

Escalating doses of CUE-101 monotherapy or in combination with pembrolizumab as evaluated in patients with HPV16+ recurrent/metastatic head and neck...